Denali Therapeutics holder plans sale of 2,857 shares

A holder of Denali Therapeutics Inc. common stock submitted a notice to sell 2,857 shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ market.

Rhea-AI Filing Summary

A holder of Denali Therapeutics Inc. common stock submitted a notice to sell 2,857 shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ market. The shares relate to a restricted stock lapse dated 08/10/2026 and are tied to equity compensation, with an indicated aggregate value of $71,623.51 as of 08/11/2026.

Key Figures

Shares to be sold: 2,857 shares Indicated aggregate value: $71,623.51 Restricted stock lapse date: 08/10/2026 +1 more

4 metrics

Shares to be sold 2,857 shares Common stock referenced in the notice

Indicated aggregate value $71,623.51 Value associated with 2,857 shares as of 08/11/2026

Restricted stock lapse date 08/10/2026 Date of restricted stock lapse tied to the equity compensation

Trading market NASDAQ Market where the shares are indicated for trading

Key Terms

Form 144, Restricted Stock Lapse, equity compensation, Executive Financial Services

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Lapse financial

"Restricted Stock Lapse - See Remarks"

equity compensation financial

"08/10/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is covered for Denali Therapeutics Inc. (DNLI)?

The notice covers a proposed sale of 2,857 shares of Denali Therapeutics Inc. common stock, arranged through Morgan Stanley Smith Barney LLC Executive Financial Services and listed for trading on the NASDAQ market.

What is the approximate value of the Denali Therapeutics (DNLI) shares to be sold?

The proposed sale involves Denali Therapeutics common stock with an indicated aggregate value of about $71,623.51. This value is associated with 2,857 shares referenced in the notice as of 08/11/2026.

How many Denali Therapeutics (DNLI) shares are planned for sale under this notice?

The notice relates to a planned sale of 2,857 shares of Denali Therapeutics Inc. common stock. These shares are connected to a restricted stock lapse and categorized as equity compensation.

What is the origin of the Denali Therapeutics (DNLI) shares in this Form 144 notice?

The shares are described as stemming from a Restricted Stock Lapse dated 08/10/2026. They are identified as equity compensation, indicating they were originally granted as part of a compensation arrangement.

Through which broker will the Denali Therapeutics (DNLI) shares be sold?

The proposed sale is arranged through Morgan Stanley Smith Barney LLC Executive Financial Services, headquartered at 1 New York Plaza, 38th Floor, New York, NY 10004, with trading indicated on the NASDAQ market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 05:40 PM Accepted by SEC EDGAR 08/11/2026 - 05:39 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001724311
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Denali Therapeutics Inc.
SEC File Number
Address of Issuer	161 Oyster Point Blvd South San Francisco CALIFORNIA 94080
Phone	6508668547
Name of Person for Whose Account the Securities are To Be Sold	Schuth Alexander O.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Fl. New York NY 10004	2857	71623.51	160062220	08/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/10/2026	Restricted Stock Lapse - See Remarks	Denali Therapeutics Inc.			2857	08/10/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Shares sold to cover tax obligation from settlement of vested Restricted Stock Units.
Date of Notice	08/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Tyler Nielsen, by power of attorney
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)